dimethyl 3-propylpentanedioate | 58219-47-9

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: dimethyl 3-propylpentanedioate
• CAS: 58219-47-9
• 化学式: C₁₀H₁₈O₄
• 分子量: 202.251
• InChiKey: NNWIJFIDQOXPKB-UHFFFAOYSA-N

物化性质

• 沸点：
  234.5±8.0 °C(Predicted)
• 密度：
  1.006±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  14
• 可旋转键数：
  8
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  52.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  dimethyl 3-propylpentanedioate 在 吡啶 、 lithium aluminium tetrahydride 、 sodium hydride 、 potassium carbonate 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 74.0h， 生成 1-{3-[2-(4'-chlorobiphenyl-4-yloxy)ethyl]hexyl}-3-pyridin-4-ylimidazolidin-2-one
  参考文献：
  名称：

  Design, Synthesis, and Antipicornavirus Activity of 1-[5-(4-Arylphenoxy)alkyl]-3-pyridin-4-ylimidazolidin-2-one Derivatives

  摘要：

  A series of pyridylimidazolidinone derivatives was synthesized and tested in vitro against enterovirus 71 (EV71). On the basis of compound 33 (DBPR103), introduction of a methyl group at the 2- or 3-position of the linker between the imidazolidinone and the biphenyl resulted in markedly improved antiviral activity toward EV71 with IC50 values of 5.0 nM (24b) and 9.3 nM (14a), respectively. Increasing the branched chain to propyl resulted in a progressive decrease in activity, while inserting different heteroatoms entirely rendered the compound only weakly active. The introduction of a bulky group (cyclohexyl, phenyl, or benzyl) led to loss of activity against EV71. The 4-chlorophenyl moiety in 14a was replaced with bioisosteric groups such as oxadiazole (28a-d) or tetrazole (32a,b), dramatically improving anti-EV71 activity and selectivity indices. Compounds 14a, 24b, 28b, 28d, and 32a exhibited a strong activity against lethal EV71, and no apparent cellular toxicity was observed. Three of the more potent imidazolidinone compounds, 14a, 28b, and 32b, were subjected to a large group of picornaviruses to determine their spectrum of antiviral activity.

  DOI：

  10.1021/jm050033v
• 作为产物：
  描述：

  3-丙基戊二酸 在 硫酸 作用下， 以82 %的产率得到dimethyl 3-propylpentanedioate
  参考文献：
  名称：

  PROCESS FOR THE PREPARATION OF (R)-4-PROPYL PYRROLIDINE-2-ONE, A KEY INTERMEDIATE FOR SYNTHESIS OF BRIVARACETAM

  摘要：

  A process for the preparation of (R)-4-propyl-pyrrolidine-2-one, is provided which includes enzymatic conversion of dimethyl 3-propyl pentanedioate selectively into (S)-3-(2-methoxy-2-oxoethyl) hexanoic acid using Novozyme's Promea® enzyme, amidation of (S)-3-(2-methoxy-2-oxoethyl) hexanoic acid, followed by ester hydrolysis to obtain (S)-3-(2-amino-2-oxoethyl) hexanoic acid having high chiral purity>99% and converting the amide to amine by Hofmann rearrangement and cyclization resulting in (R)-4-propyl-pyrrolidine-2-one. It is further converted to Brivaracetam by N-alkylation with 2-bromobutyric acid, esterification followed by enzymatic resolution.

  公开号：

  US20230373914A1

文献信息

• Preparation of chiral δ-lactones via enantiotopically specific pig liver esterase-catalysed hydrolyses of 3-substituted glutaric acid diesters
  作者：Christopher J. Francis、J. Bryan Jones

  DOI：10.1039/c39840000579

  日期：——

  Pig liver esterase-catalysed hydrolyses of 3-monosubstituted glutaric acid diesters are pro-S enantiotopically specific for a broad range of C-3 substituents and permit either enantiomer of the corresponding 3-substituted valerolac- tones of 100% e.e. to be readily prepared.

  的3-单取代的戊二酸的二酯猪肝酯酶催化的水解是亲- š enantiotopically特异于范围广泛的C-3取代基，并允许任一相应的3-取代的valerolac-音调100％容易地制备EE的对映体。
• PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE 3-SUBSTITUTED GLUTARIC ACID MONOAMIDE
  申请人：Kaneka Corporation

  公开号：EP2518050A1

  公开（公告）日：2012-10-31

  The process for producing an optically active 3-substituted glutaric acid monoamide is characterized in comprising the step of precipitating the optically active 3-substituted glutaric acid monoamide by mixing an acid and a mixed liquid containing an optically active 3-substituted glutaric acid monoamide represented by the following formula (2): wherein * indicates an asymmetric carbon atom; R1 is a C1-8 alkyl group, a C2-8 alkenyl group, a C2-8 alkynyl group, a C4-20 aryl group or a C5-20 aralkyl group; and the alkyl group, the alkenyl group, the alkynyl group, the aryl group and the aralkyl group may have a substituent, a basic compound, water and an organic solvent.

  生产光学活性的3-取代戊二酸单酰胺的过程的特点在于包括通过混合含有下列式(2)所表示的光学活性的3-取代戊二酸单酰胺的混合液和酸来沉淀光学活性的3-取代戊二酸单酰胺的步骤：其中*表示不对称碳原子；R1是C1-8烷基、C2-8烯基、C2-8炔基、C4-20芳基或C5-20芳基烷基；烷基、烯基、炔基、芳基和芳基烷基可能有取代基，碱性化合物，水和有机溶剂。
• Design, Synthesis, and Antipicornavirus Activity of 1-[5-(4-Arylphenoxy)alkyl]-3-pyridin-4-ylimidazolidin-2-one Derivatives
  作者：Chih-Shiang Chang、Ying-Ting Lin、Shin-Ru Shih、Chung-Chi Lee、Yen-Chun Lee、Chia-Liang Tai、Sung-Nien Tseng、Jyh-Haur Chern

  DOI：10.1021/jm050033v

  日期：2005.5.1

  A series of pyridylimidazolidinone derivatives was synthesized and tested in vitro against enterovirus 71 (EV71). On the basis of compound 33 (DBPR103), introduction of a methyl group at the 2- or 3-position of the linker between the imidazolidinone and the biphenyl resulted in markedly improved antiviral activity toward EV71 with IC50 values of 5.0 nM (24b) and 9.3 nM (14a), respectively. Increasing the branched chain to propyl resulted in a progressive decrease in activity, while inserting different heteroatoms entirely rendered the compound only weakly active. The introduction of a bulky group (cyclohexyl, phenyl, or benzyl) led to loss of activity against EV71. The 4-chlorophenyl moiety in 14a was replaced with bioisosteric groups such as oxadiazole (28a-d) or tetrazole (32a,b), dramatically improving anti-EV71 activity and selectivity indices. Compounds 14a, 24b, 28b, 28d, and 32a exhibited a strong activity against lethal EV71, and no apparent cellular toxicity was observed. Three of the more potent imidazolidinone compounds, 14a, 28b, and 32b, were subjected to a large group of picornaviruses to determine their spectrum of antiviral activity.
• PROCESS FOR THE PREPARATION OF (R)-4-PROPYL PYRROLIDINE-2-ONE, A KEY INTERMEDIATE FOR SYNTHESIS OF BRIVARACETAM
  申请人：DIVI'S LABORATORIES LTD.

  公开号：US20230373914A1

  公开（公告）日：2023-11-23

  A process for the preparation of (R)-4-propyl-pyrrolidine-2-one, is provided which includes enzymatic conversion of dimethyl 3-propyl pentanedioate selectively into (S)-3-(2-methoxy-2-oxoethyl) hexanoic acid using Novozyme's Promea® enzyme, amidation of (S)-3-(2-methoxy-2-oxoethyl) hexanoic acid, followed by ester hydrolysis to obtain (S)-3-(2-amino-2-oxoethyl) hexanoic acid having high chiral purity>99% and converting the amide to amine by Hofmann rearrangement and cyclization resulting in (R)-4-propyl-pyrrolidine-2-one. It is further converted to Brivaracetam by N-alkylation with 2-bromobutyric acid, esterification followed by enzymatic resolution.